The effect of tolvaptan on kidney function in patients with autosomal dominant polycystic kidney disease
详细信息 查看全文
- 作者：Tomoyuki Kawada
- 关键词：Estimated glomerular filtration rate ; Autosomal dominant polycystic kidney disease ; Tolvaptan ; Validity
- 刊名：Clinical and Experimental Nephrology
- 出版年：2016
- 出版时间：February 2016
- 年：2016
- 卷：20
- 期：1
- 页码：147-148
- 全文大小：296 KB
- 参考文献：1.Muto S, Kawano H, Higashihara E, Narita I, Ubara Y, Matsuzaki T, et al. The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial. Clin Exp Nephrol. 2015. doi:10.1007/s10157-015-1086-2 .
2.Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367:2407–18.PubMedCentral CrossRef PubMed
3.Kawada T. Validating GFR estimating samples with clinical outcomes. Am J Kidney Dis. 2014;63:859.CrossRef PubMed
4.Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRef PubMed
5.Horio M, Imai E, Yasuda Y, Watanabe T, Matsuo S. Modification of the CKD epidemiology collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates. Am J Kidney Dis. 2010;56:32–8.CrossRef PubMed - 作者单位：Tomoyuki Kawada (1)
1. Department of Hygiene and Public Health, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-Ku, Tokyo, 113-8602, Japan - 刊物类别：Medicine
- 刊物主题：Medicine & Public Health
Nephrology
Internal Medicine
Urology and Andrology - 出版者：Springer Japan
- ISSN：1437-7799
文摘